BiomX (PHGE) Registration filing summary

Company overview and business model

• Transitioned from a clinical-stage biopharmaceutical company to a diversified defense, security, and critical infrastructure technology portfolio in late 2025 and 2026.

• Operations now focus on three subsidiaries: DFSL (LADAR-based detection), Zorronet (AI-powered security), and X Security (defense and first-response tech).

• Recent acquisitions include 100% of Zorronet and 60% of DFSL, with strategic advisory from a former Mossad deputy head.

• Discontinued legacy phage therapy programs and dissolved former Israeli subsidiary due to insolvency.

Financial performance and metrics

• Audit opinion for FY2025 included a going concern qualification due to recurring losses and capital deficiency.

• As of December 31, 2025, reported a stockholders' deficit of $(1,302,000) and continued net losses.

• Zorronet and DFSL financials also raise substantial doubt about their ability to continue as going concerns.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for general corporate purposes.

• Assumed contingent earnout and bonus payment obligations tied to acquired subsidiaries' future performance.